Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1. Principles of shared follow-up care for early breast cancer

Principles of shared follow-up care for early breast cancer canceraustralia.gov.au Principles of shared follow-up care for early breast cancer SHARED FOLLOW-UP AND SURVIVORSHIP CARE FOR EARLY BREAST CANCER Cancer Australia’s seven Principles of shared follow-up care for early breast cancer are designed to underpin the delivery of shared follow-up and survivorship care for early breast cancer by health professionals and health services. Person-centred care The individual and their whole person (...) the provision of education, resources, information for people affected by cancer and pathways for access to specialist advice. Care is delivered according to best practice Provision of care is in accordance with nationally agreed standards and is outcome-focused. Individual follow-up care includes identified pathways for timely access to specialist providers as required. Support for the specialist treatment team The role of specialist care providers in the delivery of safe and effective follow-up care

2020 Cancer Australia

2. Shared follow-up care for early breast cancer: summary of evidence

Shared follow-up care for early breast cancer: summary of evidence canceraustralia.gov.au 1 The need for new models of follow-up care for breast cancer Shared follow-up care for early breast cancer is an innovative model of care that supports the provision of holistic follow-up and survivorship care following active treatment. With high incidence and increasing survivorship following a diagnosis of breast cancer, progressively more people will require follow-up care, placing an increased demand (...) on Australia’s health system and resources. Shared care leverages the skills and expertise of the specialist and primary care workforce to support the delivery of high quality, safe and sustainable follow-up and survivorship care. Breast cancer will affect 1 in 7 people in Australia in their lifetime. It is estimated that 19,535 people will be diagnosed with the disease in Australia in 2019 (19,371 women and 164 men). 1 Australians experience some of the highest cancer survival rates in the world. 2,3 Breast

2020 Cancer Australia

3. Role of intermittent pneumatic compression in the treatment of breast cancer-related lymphoedema: a randomized controlled trial

Role of intermittent pneumatic compression in the treatment of breast cancer-related lymphoedema: a randomized controlled trial Role of Intermittent Pneumatic Compression in the Treatment of Breast Cancer-Related Lymphoedema: A Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features (...) a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Clin Rehabil Actions , 269215519888792 2019 Dec 4 [Online ahead of print] Role of Intermittent Pneumatic Compression in the Treatment of Breast Cancer-Related Lymphoedema: A Randomized Controlled Trial , , , , , , Affiliations Expand Affiliations 1 Department of Physical Medicine

2020 EvidenceUpdates

4. OWise mobile app and website for supporting women with breast cancer - Innovative Medical Technology Overview

OWise mobile app and website for supporting women with breast cancer - Innovative Medical Technology Overview IMTO | 1 IMTO 02-20 January 2020 OWise mobile app and website for supporting women with breast cancer Innovative Medical Technology Overview Key points ? OWise Breast Cancer is an app and website that offer a suite of tailored information and tools to support women with breast cancer. ? Included in the OWise app is information on disease pathology and care pathways, tailored questions (...) to prompt discussion with healthcare practitioners, an audio- recording function for use in consultations, a symptom tracker and an appointment diary. The ability to share patient symptom data in real-time with the NHSScotland TrakCare® patient record system is being evaluated in NHS Lothian. ? The OWise app is designed for use throughout the patient journey, in conjunction with standard treatments for breast cancer, as a replacement for paper-based support tools. ? There are currently no published

2020 SHTG Advice Statements

5. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer T echnology appraisal guidance Published: 15 January 2020 www.nice.org.uk/guidance/ta619 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

6. Improved sleep after Qigong exercise in breast cancer survivors: A pilot study. (PubMed)

Improved sleep after Qigong exercise in breast cancer survivors: A pilot study. Sleep disorder and fatigue are among a few major concerns of breast cancer survivors across the survivorship trajectory. The purpose of this pilot study was to examine feasibility and trends in multiple outcomes after a 6-week Qigong exercise program in breast cancer survivors.Eight female adults (mean age 55.4 ± 9.4 years, mean time after the completion of cancer treatment 3.9 ± 5.7 years) who had a diagnosis (...) of breast cancer and were at least 3 months postcompletion of primary cancer treatment prior to participation in this study. Baseline evaluation was administered using subjective questionnaires on sleep quality, insomnia, fatigue, and quality of life. All subjects participated in two training sessions to learn the "Six Healing Sound" Qigong exercise and attended group Qigong sessions once per week in the following 6 weeks. In addition to the group sessions, subjects were asked to perform the Qigong

Full Text available with Trip Pro

2019 Asia-Pacific journal of oncology nursing Controlled trial quality: uncertain

7. Effectiveness of Mindfulness-Based Art Therapy on Healthy Quality of Life in Women with Breast Cancer. (PubMed)

Effectiveness of Mindfulness-Based Art Therapy on Healthy Quality of Life in Women with Breast Cancer. The purpose of this study was to determine the effectiveness of mindfulness-based art therapy (MBAT) in promoting quality of life in Neyshabur women with breast cancer.This study was an interventional design that was conducted on 124 women with breast cancer (any stage) in Iran 2018. One hundred and fourteen women with breast cancer were paired by age and randomized to either 12-week MBAT (...) intervention group or a wait-list-control group. One hundred and fourteen women with breast cancer completed both the pre-and post-study measurements. As compared to the control group, the MBAT group demonstrated a significant decrease in symptoms of distress and significant improvements in key aspects of the health-related quality of life (as measured by the World Health Organization Quality-of-Life - BREF questionnaire).The MBAT interventions had a significant effect on improving quality of life

Full Text available with Trip Pro

2019 Asia-Pacific journal of oncology nursing Controlled trial quality: uncertain

8. A Comparative Study of Hypofractionated and Conventional Radiotherapy in Postmastectomy Breast Cancer Patients. (PubMed)

A Comparative Study of Hypofractionated and Conventional Radiotherapy in Postmastectomy Breast Cancer Patients. The aim of this study was to compare toxicity and locoregional control of short duration hypofractionated (HF) radiotherapy (RT) with conventional RT in breast cancer patients.A total of 100 postmastectomy breast cancer patients were randomized for adjuvant RT in control group (comprising fifty patients who received the standard conventional dose of 50 Gy in 25 fractions with 2 Gy per (...) HF RT was found to be well tolerated with mild-to-moderate side effects that neither reached statistical significance nor warranted any treatment interruption/hospitalization.HF postmastectomy RT is comparable to conventional RT without evidence of higher adverse effects or inferior locoregional tumor control and has an added advantage of increased compliance because of short duration; hence, it can help in accommodating more breast cancer patients in a calendar year, ultimately resulting

Full Text available with Trip Pro

2019 Asia-Pacific journal of oncology nursing Controlled trial quality: uncertain

9. Aerobic and Resistance Exercise Improves Shoulder Function in Women Who Are Overweight or Obese and Have Breast Cancer: A Randomized Controlled Trial

Aerobic and Resistance Exercise Improves Shoulder Function in Women Who Are Overweight or Obese and Have Breast Cancer: A Randomized Controlled Trial Adverse upper limb musculoskeletal effects occur after surgical procedures and radiotherapy for breast cancer and can interfere with activities of daily living.The objective of this study was to examine the effects of a 16-week exercise intervention on shoulder function in women who are overweight or obese and have breast cancer.This study (...) was a randomized controlled trial.The study was performed at the Division of Biokinesiology and Physical Therapy at the University of Southern California.One hundred women with breast cancer were randomly allocated to exercise or usual-care groups. The mean (SD) age of the women was 53.5 (10.4) years, 55% were Hispanic white, and their mean (SD) body mass index was 33.5 (5.5) kg/m2.The 16-week exercise intervention consisted of supervised, progressive, moderate to vigorous aerobic and resistance exercise 3

2019 EvidenceUpdates

10. Ribociclib (breast cancer; combination with fulvestrant) - Addendum to Commission A19-06

Ribociclib (breast cancer; combination with fulvestrant) - Addendum to Commission A19-06 1 Translation of addendum A19-45 Ribociclib (Mammakarzinom; Kombination mit Fulvestrant) – Addendum zum Auftrag A19-06 (Version 1.0; Status: 17 June 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 17 June 2019 1.0 Commission: A19-45 Version: Status: IQWiG (...) Reports – Commission No. A19-45 Ribociclib (breast cancer; combination with fulvestrant) – Addendum to Commission A19-06 1 Addendum A19-45 Version 1.0 Ribociclib – Addendum to Commission A19-06 17 June 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ribociclib (breast cancer; combination with fulvestrant) – Addendum to Commission A19-06 Commissioning agency: Federal Joint Committee

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

11. Ribociclib (breast cancer; combination with an aromatase inhibitor) - Addendum to Commission A19-06

Ribociclib (breast cancer; combination with an aromatase inhibitor) - Addendum to Commission A19-06 1 Translation of addendum A19-46 Ribociclib (Mammakarzinom; Kombination mit einem Aromatasehemmer) – Addendum zum Auftrag A19-06 (Version 1.0; Status: 14 June 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 14 June 2019 1.0 Commission: A19-46 (...) Version: Status: IQWiG Reports – Commission No. A19-46 Ribociclib (breast cancer; combination with an aromatase inhibitor) – Addendum to Commission A19-06 1 Addendum A19-46 Version 1.0 Ribociclib – Addendum to Commission A19-06 14 June 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ribociclib (breast cancer; combination with an aromatase inhibitor) – Addendum to Commission A19-06

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

12. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab

Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab T echnology appraisal guidance Published: 20 November 2019 www.nice.org.uk/guidance/ta612 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y (...) to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612) © NICE 2019. All rights

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

13. Pertuzumab (Perjeta) after surgery for some breast cancers at high risk of recurrence

Pertuzumab (Perjeta) after surgery for some breast cancers at high risk of recurrence Prescrire IN ENGLISH - Spotlight ''Sample Free Download article (titre court pour FB et Twitter)'', 1 December 2019 {1} {1} {1} | | > > > Sample Free Download article (titre court pour FB et Twitter) Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the December (...) issue of Prescrire International: pertuzumab (Perjeta°) after surgery for some breast cancers at high risk of recurrence FREE DOWNLOAD Pertuzumab (Perjeta°) is a monoclonal antibody which has been authorised for use after surgery for some breast cancers. How do Prescrire's editors rate the drug's harm-benefit balance in this situation, in light of the most recent evidence? Full text available for free download. Summary Pertuzumab (Perjeta°, Roche) is a monoclonal antibody with anti-HER2 activity

2019 Prescrire

14. Influence of delay on breast cancer surgery outcome

Influence of delay on breast cancer surgery outcome Influence of delay on breast cancer surgery outcome We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Influence of delay on breast cancer surgery outcome Share: Reading time approx. 5 minutes In Sweden as well as worldwide, breast cancer is the most common cancer diagnosis in women, and surgery (...) is the primary treatment for curative care. As the time between diagnosis and surgery can vary substantially, it is essential to know if wait time for operative procedures may influence surgery outcomes. Question What systematic reviews are there on surgical wait time and medical outcomes in breast cancer patients? Identified literature No relevant systematic reviews with low/medium risk of bias were found. SBU Enquiry Service consists of systematic literature searches to highlight studies that can address

2019 Swedish Council on Technology Assessement

15. Ribociclib (Kisqali) - breast cancer

Ribociclib (Kisqali) - breast cancer 1 Published 11 November 2019 1 SMC2198 ribociclib 200mg film-coated tablets (Kisqali ® ) Novartis Pharmaceuticals UK Ltd 04 October 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission assessed under the end of life and orphan medicine process (...) ribociclib (Kisqali ® ) is accepted for restricted use within NHSScotland. Indication under review: for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant* as initial endocrine-based therapy, or in women who have received prior endocrine therapy. SMC restriction: women who have relapsed on or within 12 months of completing (neo) adjuvant endocrine therapy

2019 Scottish Medicines Consortium

16. Neratinib (Nerlynx) - breast cancer and solid tumours

Neratinib (Nerlynx) - breast cancer and solid tumours Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you

2019 Health Canada - drugs and medical devices

17. Trastuzumab (Ogivri) - breast cancer or gastric cancer

Trastuzumab (Ogivri) - breast cancer or gastric cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1

2019 Health Canada - Drug and Health Product Register

18. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis Although international guidelines support the administration of hormone therapies with or without targeted therapies in postmenopausal women with hormone-receptor-positive, HER2-negative metastatic breast cancer, upfront use of chemotherapy remains common even in the absence of visceral crisis. Because first-line (...) trials investigating chemotherapy with or without targeted therapies and hormone therapies with or without targeted therapies as first-line or second-line treatments, or both, in postmenopausal women with hormone-receptor-positive, HER2-negative metastatic breast cancer, published between Jan 1, 2000, and Dec 31, 2017. Additional recently published randomised controlled trials relevant to the topic were also subsequently added. No language restrictions were adopted for our search. A Bayesian network

2019 EvidenceUpdates

19. Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial

Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial The addition of ovarian function suppression (OFS) for 5 years to tamoxifen (TAM) for treatment of premenopausal patients with breast cancer after completion of chemotherapy has beneficial effects on disease-free survival (DFS). This study evaluated the efficacy of adding 2 years of OFS to TAM in patients with hormone receptor-positive breast cancer who remain in a premenopausal state or resume (...) ovarian function after chemotherapy.We enrolled 1,483 premenopausal women (age ≤ 45 years) with estrogen receptor-positive breast cancer treated with definitive surgery after completing adjuvant or neoadjuvant chemotherapy. Ovarian function was assessed every 6 months for 2 years since enrollment on the basis of follicular-stimulating hormone levels and vaginal bleeding history. If ovarian function was confirmed to be premenopausal at each visit, the patient was randomly assigned to complete 5 years

2019 EvidenceUpdates

20. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy and tolerability of pyrotinib versus lapatinib, both in combination with capecitabine, in women with human epidermal growth factor receptor 2 (HER2)-positive (...) metastatic breast cancer in an open-label, multicenter, randomized phase II study.Chinese patients with HER2-positive relapsed or metastatic breast cancer previously treated with taxanes, anthracyclines, and/or trastuzumab were assigned (1:1) to receive 400 mg pyrotinib or lapatinib 1,250 mg orally once per day for 21-day cycles in combination with capecitabine (1,000 mg/m2 orally twice per day on days 1 to 14). The primary end point was investigator-assessed overall response rate per Response Evaluation

2019 EvidenceUpdates